Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT02556086 Withdrawn - Hepatitis C Clinical Trials

A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)

Start date: December 2015
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine if combination therapy with daclatasvir (DCV) and sofosbuvir (SOF) for 8 weeks is safe and effective in patients who have never been treated previously without liver cirrhosis who are chronically infected with hepatitis C virus (HCV)/HIV-1 Coinfection genotype (GT) 1, 2, 3, 4 patients.

NCT ID: NCT02462772 Withdrawn - Clinical trials for Human Immunodeficiency Virus

Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa

CAPRISA014
Start date: October 2015
Phase: Phase 2
Study type: Interventional

The CAPRISA 014 trial aims to assess the safety and acceptability of the long-acting (LA) injectable antiretroviral agent, cabotegravir LA (GSK1265744), in HIV uninfected women in KwaZulu-Natal, South Africa.

NCT ID: NCT02257788 Withdrawn - HIV Clinical Trials

PRO 140 for Human Immunodeficiency Virus Infection

Start date: September 2014
Phase: Phase 2
Study type: Interventional

PRO 140 2103 is a multicenter, randomized parallel group study, conducted in male and female adult subjects infected with CCR5-tropic HIV-1.

NCT ID: NCT01975012 Withdrawn - HIV Infections Clinical Trials

Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age

Start date: September 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Development of tolerable and effective antiretroviral (ARV) drugs for use in children and adolescents remains a high priority. First-line therapy with non-nucleoside reverse transcriptase inhibitors (NNRTIs) has proven to be effective for HIV-1-infected infants, children, and adolescents. This study will evaluate the safety, effectiveness, and dosing levels of the NNRTI rilpivirine (RPV) when given with two other ARV drugs in treatment-naive, HIV-1-infected children less than 12 years of age.

NCT ID: NCT01970449 Withdrawn - HIV Infections Clinical Trials

Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and immune response to three different sets of HIV vaccines in healthy, HIV-uninfected adults.

NCT ID: NCT01964937 Withdrawn - HIV Infections Clinical Trials

Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults

Start date: n/a
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and immune response to five different combinations of three HIV vaccines in healthy, HIV-uninfected adults.

NCT ID: NCT01927835 Withdrawn - HIV Infections Clinical Trials

Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and immune response to two different HIV vaccine regimens in healthy, HIV-uninfected people in the United States and South Africa.

NCT ID: NCT01909414 Withdrawn - HIV Infections Clinical Trials

Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV Medications

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of two HIV vaccines in HIV-1-infected young adults who are taking anti-HIV medications and have very low virus levels. This study will also look at how the immune system responds to the vaccines.

NCT ID: NCT01751100 Withdrawn - HIV Infections Clinical Trials

The Feasibility of Using a General Health Screen to Increase HIV Testing in Community Pharmacies

Start date: July 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to see if offering a general health screening tailored towards high-risk groups (African immigrants, injection drug users (IDUs), and minority men who have sex with men (MSM)) will increase human immunodeficiency virus (HIV) testing, counseling, and linkage acceptance rates in community pharmacies.

NCT ID: NCT01738555 Withdrawn - Clinical trials for Human Immunodeficiency Virus Infection

A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects

Start date: April 2013
Phase: Phase 2
Study type: Interventional

This study is an open-label extension of RFSP-AMDX-2010 study for those subjects who received treatment with amdoxovir (300 mg or 500 mg twice daily) for 12 weeks and benefited from it. This study will examine the safety and efficacy of the investigational HIV drug, amdoxovir (300 mg and 500 mg bid doses; N = up to 30) in combination with zidovudine and lopinavir/ritonavir for 36 weeks. Subjects will continue to receive either amdoxovir 300 mg twice daily or amdoxovir 500 mg twice daily, each in combination with zidovudine 300 mg twice daily and lopinavir/ritonavir (400 mg/100 mg twice daily) for additional 36 weeks.